Fisetin for Age-Related Lung Function Decline

Ongoing Lung Decline With Age Intensified Response

Recruiting Phase 2 Interventional Study
Age-Related Lung Function Decline
Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
60 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
40 (estimated)
Sponsor
Cedars-Sinai Medical Center · Other
Who this trial is looking for

This trial is looking for older adults aged 60 and above to test a treatment called fisetin for lung function. Participants will be assigned to receive either the treatment or a placebo for a short period.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am 60 years old or older.
  • I am willing to take either fisetin or a placebo.
  • I have a stable weight within the last 2 months.
  • I have a history of smoking or I have never smoked.
  • I do not have unstable chronic diseases.
  • I will maintain my usual activity level during the study.
  • My body mass index is less than 30 kg/m².

You may not be able to join if

  • I have abnormal heart tests.
  • I have used fisetin or similar supplements in the last 6 months.
  • My resting blood pressure is too high.
  • I have a known allergy to fisetin.
  • I currently have cancer.
  • I have serious ongoing health issues.
  • I have HIV or active hepatitis.
  • I am currently pregnant or breastfeeding.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adults aged 60 years and older who are physically capable of participating in study procedures; * Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (\<5-pound change); * No blood donation within 2 months before screening; absence of uns…
Contacts

Samuel Cohen, MD

424-315-0685

samuel.cohen@csmc.edu

CONTACT

Sandra Gomez

424-315-1224

sandra.gomez@cshs.org

CONTACT